FDA.reportPublic FDA data

adalimumab-bwwd 40 MG in 0.8 ML Injection

RxCUI
2640419
RxNorm name
adalimumab-bwwd 40 MG in 0.8 ML Injection
Display name
adalimumab-bwwd 40 MG in 0.8 ML Injection
Full name
adalimumab-bwwd 40 MG in 0.8 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:56

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761059Hadlimaadalimumab-bwwd351(k) InterchangeableRx2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
4774a951-3ce8-43b6-80b1-e6b23752aae6adalimumab-bwwd 40 MG in 0.8 ML Injection [PSN] · 0.8 ML adalimumab-bwwd 50 MG/ML Injection [SCD] · adalimumab-bwwd 40 MG per 0.8 ML Injection [SY]313These highlights do not include all the information needed to use HADLIMA safely and effectively. See full prescribing information for HADLIMA. HADLIMA (adalimumab-bwwd) injection, for subcutaneous use Initial U.S. Approval: 2019 HADLIMA (adalimumab-bwwd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee20251017